Cargando…

The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents

The induction of protein degradation in a highly selective and efficient way by means of druggable molecules is known as targeted protein degradation (TPD). TPD emerged in the literature as a revolutionary idea: a heterobifunctional chimera with the capacity of creating an interaction between a prot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coll-Martínez, Bernat, Delgado, Antonio, Crosas, Bernat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766482/ https://www.ncbi.nlm.nih.gov/pubmed/33339292 http://dx.doi.org/10.3390/molecules25245956

Ejemplares similares

How the 26S Proteasome Degrades Ubiquitinated Proteins in the Cell
por: Coll-Martínez, Bernat, et al.
Publicado: (2019)

Ubiquitin Signaling: Extreme Conservation as a Source of Diversity
por: Zuin, Alice, et al.
Publicado: (2014)

A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
por: Chen, Xuanrong, et al.
Publicado: (2021)

Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives
por: Esposito, Carla Lucia, et al.
Publicado: (2018)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Cannabinoid ligands, receptors and enzymes: Pharmacological tools and therapeutic potential
por: Hourani, Wafa, et al.
Publicado: (2018)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
por: Wang, Chao, et al.
Publicado: (2022)

IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential
por: Johansson, Björn P., et al.
Publicado: (2008)

Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019
por: Chen, Kuan-Hsuan, et al.
Publicado: (2020)

Therapeutic Targeting of the Proteolytic Enzymes
por: Couture, Frédéric
Publicado: (2022)

A C2HC zinc finger is essential for the RING-E2 interaction of the ubiquitin ligase RNF125
por: Bijlmakers, Marie-José, et al.
Publicado: (2016)

Tools for integrated sequence-structure analysis with UCSF Chimera
por: Meng, Elaine C, et al.
Publicado: (2006)

UCSF ChimeraX: Tools for structure building and analysis
por: Meng, Elaine C., et al.
Publicado: (2023)

Therapeutic Potential of Natural Pharmacological Agents in the Treatment of Human Diseases
por: Ramana, Kota V., et al.
Publicado: (2014)

Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms
por: Yang, Yang, et al.
Publicado: (2021)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Sphingolipids in Atherosclerosis: Chimeras in Structure and Function
por: Peters, Lisa, et al.
Publicado: (2022)

The search for the chimera
por: Randi, J
Publicado: (1991)

The pharmacology and therapeutic potential of (−)-huperzine A
por: Tun, Maung Kyaw Moe, et al.
Publicado: (2012)

Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic
por: Bhandari, Ranjana, et al.
Publicado: (2021)

An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer
por: Rajkovic, Jovana, et al.
Publicado: (2023)

Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases
por: Zhao, Longwei, et al.
Publicado: (2019)

Chimera: The spoiler in multiple displacement amplification
por: Lu, Na, et al.
Publicado: (2023)

Amelioration of hepatotoxicity by biocleavable aminothiol chimeras of isoniazid: Design, synthesis, kinetics and pharmacological evaluation
por: Bhilare, Neha Vithal, et al.
Publicado: (2018)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Proteolysis-targeting chimeras and their implications in breast cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2021)

The clinical advances of proteolysis targeting chimeras in oncology
por: Xie, Hao, et al.
Publicado: (2021)

Alvis: a tool for contig and read ALignment VISualisation and chimera detection
por: Martin, Samuel, et al.
Publicado: (2021)

Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy
por: Hmadcha, Abdelkrim, et al.
Publicado: (2020)

Triazole analogues as potential pharmacological agents: a brief review
por: Kumar, Sachin, et al.
Publicado: (2021)

Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents
por: Kumar Kulabhusan, Prabir, et al.
Publicado: (2020)

Extracellular vesicles: Emerging tools as therapeutic agent carriers
por: Liu, Shan, et al.
Publicado: (2022)

MT1-MMP-dependent cell migration: proteolytic and non-proteolytic mechanisms
por: Gifford, Valentina, et al.
Publicado: (2019)

The proteolytic landscape of the yeast vacuole
por: Hecht, Karen A, et al.
Publicado: (2014)

Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19
por: Vitiello, A., et al.
Publicado: (2020)

Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome
por: Lai, Ruenn Chai, et al.
Publicado: (2012)

Assays and technologies for developing proteolysis targeting chimera degraders
por: Liu, Xingui, et al.
Publicado: (2020)

Hunting Down the Chimera of Multiple Disciplinarity in Conservation Science
por: POOLEY, SIMON P, et al.
Publicado: (2014)

Therapeutic Potential of Curcumin as an Antimycobacterial Agent
por: Barua, Nilakshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r1sg4na4pi6t7n81ak16gc21gi